In summary, our study not only reveals a critical role of the PML-RARα/PPARγ/TRIB3 axis in dyslipidemia for patients with APL but also confers a rationale for the combination of ATRA/arsenic with the PPAR activator for the treatment of patients with APL. Here, PML is linked to metabolic syndrome.